Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 20/20 | 0.73 |
| ▸ | ITGA4 | P13612 | 20/20 | 0.73 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.64 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4809695 | 0.87 | ITGB1 (0.71) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7610444 | 0.82 | ITGA4 (0.74) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7612126 | 0.81 | ITGA4 (0.79) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7614114 | 0.81 | ITGB1 (0.73) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL180926 | 0.80 | ITGB1 (0.64) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL4814347 | 0.80 | ITGB1 (0.64) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL2842957 | 0.80 | PRKCI (0.55) | ITGB1ITGA4 | |
| SCHEMBL14305627 | 0.80 | PRKCI (0.55) | ITGB1ITGA4 | |
| SCHEMBL6562715 | 0.79 | ITGB1 (0.77) | ITGB1ITGA4ITGA2ITGB7 | |
| SCHEMBL7538961 | 0.79 | ITGB1 (0.73) | ITGB1ITGA4ITGA2ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020035127-A1 | Phenylalanine derivatives | CELLTECH THERAPEUTIS, LIMITED | 2002-03-21 | — | — | US | disclosed |
| US-6329372-B1 | HETEROCYCLIC AMIDE COMPOUNDS ARE ABLE TO INHIBIT THE BINDING OF ALPHA4 INTEGRINS TO THEIR LIGANDS AND ARE OF USE IN THE PROPHYLAXIS AND TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS. | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035127-A1 | Phenylalanine derivatives | PAH, VCAM1, IL4I1 | ITGB1 8/4885ITGA4 5/4885ITGA2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.